Eli Lilly reported new clinical data indicating its oral obesity drug Foundayo (orforglipron) also improves obstructive sleep apnea outcomes. In results published in JAMA, the GLP-1 pill reduced sleep apnea severity at 52 weeks in participants who were not using positive airway pressure therapy, and it improved outcomes as well among those using PAP. The trial findings position the oral incretin as a potential therapeutic option beyond weight loss, with secondary measures also reported to improve blood pressure and inflammation alongside breathing-related endpoints. The study builds on ongoing industry interest in GLP-1-based interventions for cardiometabolic and respiratory comorbidities. For GLP-1 competitors and prescribers, the timing matters: regulatory attention on NAION risk is now intersecting with additional clinical utility claims across obesity-related disease burdens. Any path to broader adoption will likely depend on the label scope, durability of respiratory benefits, and how clinicians weigh incremental sleep apnea efficacy against class safety communications.